![Natalie Holles](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Natalie Holles
Chief Executive Officer at
AURA BIOSCIENCES, INC.
Net worth: 9 M $ as of 31/05/2026
Profile
Natalie C.
Holles is President, Chief Executive Officer & Director at Aura Biosciences, Inc. since 2026.
Ms. Holles is Director at LeonaBio, Inc. since 2026.
Ms. Holles is Director at DOT Therapeutics-2, Inc. since 2021.
Ms. Holles was President, Chief Executive Officer & Director at Astellas Gene Therapies, Inc. from 2020 to 2021.
Ms. Holles was Chief Executive Officer & Director at Third Harmonic Bio, Inc. from 2021 to 2025.
Ms. Holles was Independent Director at Allakos, Inc. from 2020 to 2021.
Ms. Holles was Independent Director at Rubius Therapeutics, Inc. from 2019 to 2022.
Ms. Holles was Independent Director at Day.
One Biopharmaceuticals, Inc. from 2022 to 2026.
Ms. Holles was Principal at InterMune, Inc. Ms. Holles was Vice President-Business Development at KAI Pharmaceuticals, Inc. from 2005 to 2010.
Ms. Holles was Senior VP-Corporate & Business Development at Hyperion Therapeutics, Inc. from 2013 to 2015.
Ms. Holles was Executive Vice President-Corporate Development at Immune Design Corp.
from 2012 to 2013.
Ms. Holles was Head-Business Development at Genentech, Inc. from 1999 to 2000.
Ms. Holles completed undergraduate education at Stanford University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AURA BIOSCIENCES INC 1.86% | 19/05/2026 | 11,53,962 ( 1.86% ) | 9 M $ | 31/05/2026 |
LEONABIO, INC. -.--% | 05/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Natalie Holles active positions
| Companies | Position | Start |
|---|---|---|
| AURA BIOSCIENCES, INC. | Chief Executive Officer | 30/04/2026 |
| LEONABIO, INC. | Director/Board Member | 05/05/2026 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drugs | Director/Board Member | 17/02/2021 |
Former positions of Natalie Holles
| Companies | Position | End |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Director/Board Member | 23/04/2026 |
| THIRD HARMONIC BIO, INC. | Chief Executive Officer | 01/12/2025 |
| RUBIUS THERAPEUTICS | Director/Board Member | 09/08/2022 |
| ALLAKOS INC. | Director/Board Member | 06/08/2021 |
| AUDENTES THERAPEUTICS, INC. | Chief Executive Officer | 01/03/2021 |
Training of Natalie Holles
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
59
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that researches and develops therapies in pulmonology & orphan fibrotic diseases | Health Technology |
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical drugs | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
LeonaBio, Inc.
 LeonaBio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Allakos, Inc.
 Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
University of Colorado Boulder
 University of Colorado Boulder Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Develops red cell therapeutics for cancer treatment | Health Technology |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drugs | Health Technology |
Third Harmonic Bio, Inc.
 Third Harmonic Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of allergic and immune diseases and disorders | Health Technology |
Day One Biopharmaceuticals, Inc.
 Day One Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops and commercializes targeted therapies for cancers | Health Technology |
- Stock Market
- Insiders
- Natalie Holles
